9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 125

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Disease Control rate assessed by CT scan,  Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,  Progression-Free Survival, Overall Survival

Interventions: Nivolumab, Nivolumab + Ipilimumab

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: February 2018

Completion Date: December 2019

Last  Posted Date: February 26, 2019

Location: Angers – CHU, Angers, France

Website Link: https://ClinicalTrials.gov/show/NCT02716272

Was this article helpful?
Dislike 0